

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

Technology appraisals 27  
ICB commissioned 8  
Non-ICB commissioned 12  
Not applicable 7  
ICB commissioned and approved 5 (63%)  
Average days to compliance 57

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) [TA1052]</a>	Terminated appraisal	02/04/2025	TA					N/A	Terminated appraisal
<a href="#">Eftasoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over [TA1051]</a>	Recommended	02/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over [TA1054]</a>	Recommended	15/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts / tertiary providers.	NHS England
<a href="#">Cladribine for treating active relapsing forms of multiple sclerosis [TA1053]</a>	Recommended	15/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [TA1057]</a>	Recommended	16/04/2025	TA	15/07/2025	ICB	19/06/2025	64	This technology is commissioned by integrated care boards. Providers are Primary care and NHS hospital trusts.	Amber initiated RAG rating
<a href="#">Molnupiravir for treating COVID-19 [TA1056]</a>	Recommended	16/04/2025	TA	15/07/2025	ICB	19/06/2025	64	This technology is commissioned by integrated care boards. Providers are Primary care providers and NHS hospital trusts.	Red RAG rating
<a href="#">Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [TA1055]</a>	Recommended	16/04/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) [TA1058]</a>	Terminated appraisal	23/04/2025	TA					N/A	Terminated appraisal
<a href="#">Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 [TA878]</a>	Recommended	01/05/2025	TA (Update)	01/05/2025	ICB			This technology is commissioned by integrated care boards. Providers are NHS Hospital trusts and primary care.	Red RAG rating
<a href="#">Cenobamate for treating focal onset seizures in epilepsy [TA753]</a>	Recommended	06/05/2025	TA (Update)	06/05/2025	ICB			This technology is commissioned by integrated care boards. Providers are NHS Hospital trusts and primary care.	Amber initiated RAG rating
<a href="#">Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)</a>	Terminated appraisal	06/05/2025	TA					N/A	Terminated appraisal
<a href="#">Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma [TA1059]</a>	Recommended	07/05/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [TA1060]</a>	Recommended	08/05/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor [TA1062]</a>	Recommended	12/05/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Capiivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [TA1063]</a>	Recommended	15/05/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
<a href="#">Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [TA1064]</a>	Recommended	22/05/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [TA1065]</a>	Recommended	28/05/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) [TA1068]</a>	Terminated appraisal	29/05/2025	TA					N/A	Terminated appraisal
<a href="#">Somapacitan for treating growth hormone deficiency in people 3 to 17 years [TA1066]</a>	Recommended	03/06/2025	TA (Cost comparison)	03/07/2025	ICB	17/07/2025	44	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating
<a href="#">Efgartiqimod for treating antibody-positive generalised myasthenia gravis [TA1069]</a>	Not recommended	04/06/2025	TA					N/A	Not recommended
<a href="#">Linzagolix for treating symptoms of endometriosis [TA1067]</a>	Recommended	04/06/2025	TA	02/09/2025	ICB			This technology is commissioned by integrated care boards. Providers are NHS Hospital trusts and primary care.	Amber retained RAG rating proposed
<a href="#">Spesolimab for treating generalised pustular psoriasis flares [TA1070]</a>	Recommended	18/06/2025	TA	16/09/2025	ICB			This technology is commissioned by integrated care boards. Providers are NHS hospital trusts - acute and Tertiary care	Red RAG rating proposed
<a href="#">Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) [TA1072]</a>	Terminated appraisal	19/06/2025	TA					N/A	Terminated appraisal
<a href="#">Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [TA1071]</a>	Recommended	19/06/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies [TA1073]</a>	Partially recommended	24/06/2025	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
<a href="#">Sparsentan for treating primary IgA nephropathy [TA1074]</a>	Recommended	25/06/2025	TA	23/09/2025	ICB			This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red RAG rating proposed
<a href="#">Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) [TA1078]</a>	Terminated appraisal	25/06/2025	TA					N/A	Terminated appraisal